TOBRAMYCIN
THERAPY
OF
PULMONARY
INFECTIONS
IN
PATIENTS
WITH
CYSTIC
FIBROSIS
SIX
PATIENTS
HAVING
EXACERBATIONS
OF
CHRONIC
PULMONARY
INFECTIONS
IN
ASSOCIATION
WITH
CYSTIC
FIBROSIS
WERE
TREATED
WITH
INTRAMUSCULAR
TOBRAMYCIN
5
MGKGDAY
IN
3
DIVIDED
DOSES
THE
EIGHT
TREATMENT
COURSES
LASTED
9
TO
30
DAYS
MEAN
SERUM
LEVELS
WERE
25
MICROGML
AT
1
TO
3
HOURS
AND
02
MICROGML
AT
7
12
TO
8
HOURS
AFTER
A
DOSE
OF
TOBRAMYCIN
THE
MEAN
TOBRAMYCIN
CONCENTRATION
IN
SPUTUM
WAS
03
MICROGML
EIGHTYTWO
PERCENT
OF
THE
66
PATHOGENIC
BACTERIAL
ISOLATES
FROM
SPUTUM
WERE
EITHER
PSEUDOMONAS
SP
64
OR
STAPHYLOCOCCUS
AUREUS
18
NINETYSEVEN
PERCENT
OF
PSEUDOMONAS
SP
AND
83
PERCENT
OF
STAPHYLOCOCCUS
AUREUS
WERE
INHIBITED
BY
31
MICROG
TOBRAMYCIN
PER
ML
NO
ORGANISM
THAT
WAS
ISOLATED
BEFORE
THERAPY
WAS
OBSERVED
TO
BECOME
RESISTANT
TO
TOBRAMYCIN
ALTHOUGH
ON
3
OCCASIONS
COLONIZATION
WITH
NEW
RESISTANT
GRAMNEGATIVE
BACILLI
OCCURRED
IN
6
OUT
OF
8
COURSES
OF
THERAPY
PATIENTS
SHOWED
CLINICAL
IMPROVEMENT
ELIMINATION
OF
BACTERIAL
PATHOGENS
FROM
THE
SPUTUM
WAS
RARELY
ACHIEVED
AND
WAS
NOT
NECESSARY
TO
PRODUCE
CLINICAL
IMPROVEMENT
COLONIZATION
WITH
RESISTANT
FLORA
WAS
AN
UNCOMMON
FINDING
TOBRAMYCINS
SIDE
EFFECTS
WERE
LIMITED
TO
LOCAL
DISCOMFORT
AT
THE
INJECTION
SITE
NAUSEA
AND
VOMITING
